Kava fatalities in MMWR
This article was originally published in The Tan Sheet
Executive Summary
Possibility of hepatic toxicity associated with use of kava products reported in CDC's Nov. 29 Morbidity & Mortality Weekly Report. MMWR summarizes two case reports: the first involves a 45-year-old woman who underwent liver transplantation after being hospitalized for jaundice and hepatitis following regular use of a kava-containing dietary supplement; the second involves a 14-year-old girl diagnosed with scleral icterus and acute hepatitis following a four-month period of semi-regular kava use. FDA issued a consumer advisory on the botanical earlier this year (1"The Tan Sheet" April 1, 2002)...
You may also be interested in...
Kava AERs not linked to fatalities
Two reports of hepatic toxicity associated with kava and appearing in CDC's Nov. 29 Morbidity & Mortality Weekly Report were not fatalities, as reported in 1"The Tan Sheet" Dec. 2, 2002, p. 6. Patients in both case reports recovered following their illnesses...
Kava Labeling Revisions Adopted By Trade Groups; FDA Issues Advisory
Various dietary supplement trade associations adopted revised kava labeling requirements for their member companies following the release of an 1FDA consumer advisory on the botanical
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.